Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RWJ-445380 in Plaque Psoriasis
NCT00396422Phase 2Completed
- Sponsor
- ALZA Corporation
- Start
- Sep 2006
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of RWJ-445380 in plaque psoriasis (5 arms), sponsored by ALZA Corporation. Primary endpoint: Safety and Tolerability at 12 weeks. Started Sep 2006; status: completed.
02
Drugs
RWJ-445380
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00396422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396422.